[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60027135D1 - Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen - Google Patents

Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen

Info

Publication number
DE60027135D1
DE60027135D1 DE60027135T DE60027135T DE60027135D1 DE 60027135 D1 DE60027135 D1 DE 60027135D1 DE 60027135 T DE60027135 T DE 60027135T DE 60027135 T DE60027135 T DE 60027135T DE 60027135 D1 DE60027135 D1 DE 60027135D1
Authority
DE
Germany
Prior art keywords
inhibitors
applications
differentiation factor
growth differentiation
gdf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60027135T
Other languages
English (en)
Other versions
DE60027135T2 (de
Inventor
Stavros Topouzis
F Wright
Tamara Ratovitski
Li-Fang Liang
L Brady
Debasish Sinha
Linda Yaswen-Corkery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MetaMorphix Inc
Original Assignee
MetaMorphix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26814445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60027135(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MetaMorphix Inc filed Critical MetaMorphix Inc
Publication of DE60027135D1 publication Critical patent/DE60027135D1/de
Application granted granted Critical
Publication of DE60027135T2 publication Critical patent/DE60027135T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/30—Bird
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
DE60027135T 1999-01-21 2000-01-21 Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen Expired - Lifetime DE60027135T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11663999P 1999-01-21 1999-01-21
US116639P 1999-01-21
US13836399P 1999-06-10 1999-06-10
US138363P 1999-06-10
PCT/US2000/001552 WO2000043781A2 (en) 1999-01-21 2000-01-21 Growth differentiation factor inhibitors and uses therefor

Publications (2)

Publication Number Publication Date
DE60027135D1 true DE60027135D1 (de) 2006-05-18
DE60027135T2 DE60027135T2 (de) 2007-01-11

Family

ID=26814445

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60027135T Expired - Lifetime DE60027135T2 (de) 1999-01-21 2000-01-21 Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen

Country Status (12)

Country Link
EP (1) EP1147413B1 (de)
JP (1) JP2003517580A (de)
CN (1) CN100567322C (de)
AT (1) ATE322681T1 (de)
AU (2) AU772694B2 (de)
BR (1) BR0008188A (de)
CA (1) CA2359242C (de)
DE (1) DE60027135T2 (de)
HK (1) HK1041521B (de)
MX (1) MXPA01007366A (de)
NZ (1) NZ513642A (de)
WO (1) WO2000043781A2 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
EP1790726B1 (de) * 2001-02-08 2013-07-03 Wyeth LLC Modifizierte und stabilisierte GDF-Propeptide und ihre Verwendung
US6734289B2 (en) 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
US7629317B2 (en) 2001-03-29 2009-12-08 The University Of Chicago Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
ATE333469T1 (de) * 2001-06-05 2006-08-15 Genetics Inst Llc Verfahren zur reinigung hochanionischer proteine
US20040248121A1 (en) * 2001-07-11 2004-12-09 Ravi Kambadur Bioassay for myostatin
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
EP1572909A4 (de) 2002-02-21 2007-06-06 Wyeth Corp Protein mit follistatindomäne
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
KR20140004805A (ko) 2002-12-20 2014-01-13 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
JP5110877B2 (ja) 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
US7625867B2 (en) 2004-03-26 2009-12-01 Acceleron Pharma Inc. BMP-3 propeptides and related methods
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
EP1771557B1 (de) 2004-06-24 2014-12-31 Acceleron Pharma Inc. GDF3-Propeptide und damit zusammenhängende Verfahren
EP3059245B1 (de) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii-rezeptor antagonistische antikörper
MX2007001118A (es) * 2004-07-29 2007-03-15 Schering Plough Ltd Uso de inhibidores cinasa semejante a activina 5 para modular o inhibir la actividad de miostatina llevando a acrecion incrementada del tejido magro en los animales.
EP1864138A2 (de) * 2005-03-23 2007-12-12 Wyeth Erkennung von gdf-8 modulierenden wirkstoffen
MX2007011405A (es) * 2005-03-23 2007-10-11 Wyeth Corp Deteccion de una respuesta inmune para agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8).
US8017576B2 (en) 2005-05-10 2011-09-13 The University Of Chicago Methods and compositions to treat mucositis
SI1915397T1 (sl) 2005-08-19 2015-05-29 Wyeth Llc Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
EP1951756B1 (de) 2005-10-06 2015-01-07 Eli Lilly And Company Anti-myostatin-antikörper
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
JP5261187B2 (ja) 2005-11-23 2013-08-14 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａアンタゴニストおよび骨成長を促進するための使用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
WO2008030706A2 (en) 2006-09-05 2008-03-13 Eli Lilly And Company Anti-myostatin antibodies
KR101831534B1 (ko) 2006-12-18 2018-02-22 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉ 길항물질과 적혈구 수준을 증가시키기 위한 이의 용도
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
BRPI0806861A2 (pt) 2007-02-01 2014-08-05 Acceleron Pharma Inc Antagonistas de ativina-actriia e usos para tratar ou prevenir câncer de mama
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
WO2008100384A2 (en) 2007-02-09 2008-08-21 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PL2340031T4 (pl) 2008-08-14 2020-12-28 Acceleron Pharma Inc. Zastosowanie pułapek GDF do leczenia niedokrwistości
AU2009320364B2 (en) 2008-11-26 2013-05-16 Amgen Inc. Variants of activin IIB receptor polypeptides and uses thereof
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
CN102656187A (zh) 2009-06-12 2012-09-05 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
CA2770822C (en) 2009-08-13 2020-03-24 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
EP2483300A4 (de) * 2009-10-01 2013-02-27 Covita Ltd Synthetische myostatinpeptid-antagonisten
CA2779472C (en) 2009-11-03 2021-03-16 Acceleron Pharma Inc. The use of a composition comprising an activin type iib receptor polypeptide in the treatment of fatty liver disease
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
CN103987403B (zh) 2011-10-17 2017-12-01 阿塞勒隆制药公司 用于治疗无效性红细胞生成的方法和组合物
SG11201403367YA (en) 2011-12-19 2014-07-30 Amgen Inc Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
HUE049217T2 (hu) 2012-08-01 2020-09-28 Ikaika Therapeutics Llc Szövetkárosodás és fibrózis enyhítése LTBP4 elleni ellenanyaggal
US9145433B2 (en) 2012-10-05 2015-09-29 Rigel Pharmaceuticals, Inc. GDF-8 inhibitors
KR102279522B1 (ko) 2012-11-02 2021-07-19 셀진 코포레이션 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
SG10201706148WA (en) 2013-02-01 2017-08-30 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
SG11201508681QA (en) 2013-05-06 2015-11-27 Scholar Rock Inc Compositions and methods for growth factor modulation
MX2016013635A (es) 2014-04-18 2017-02-02 Acceleron Pharma Inc Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes.
CN106795224B (zh) 2014-06-04 2021-05-18 阿塞勒隆制药公司 用促滤泡素抑制素多肽治疗病症的方法和组合物
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3221318B1 (de) 2014-11-21 2021-08-25 Rigel Pharmaceuticals, Inc. Kondensierte imidazolderivate als inhibitoren des transforming growth factor beta (tgf-beta)
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
PT3227675T (pt) 2014-12-03 2023-05-30 Celgene Corp Antagonistas da ativina-actrii e utilizações para tratamento da síndrome mielodisplásica
ES2928084T3 (es) 2015-02-20 2022-11-15 Rigel Pharmaceuticals Inc Inhibidores de GDF-8
JP6836998B2 (ja) 2015-03-02 2021-03-03 ライジェル ファーマシューティカルズ， インコーポレイテッド ＴＧＦ−β阻害剤
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
US11021468B2 (en) 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
US10227393B2 (en) 2015-04-06 2019-03-12 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
HUE054180T2 (hu) 2015-04-06 2021-08-30 Acceleron Pharma Inc Egykarú I. típusú és II. típusú receptorral rendelkezõ fúziós fehérjék, illetve ezek alkalmazásai
BR112017022658A2 (pt) 2015-04-22 2018-07-17 Alivegen Usa Inc proteína isolada, molécula de ácido nucleico isolada, vetor recombinante, célula hospedeira, método de produção de uma proteína actriib híbrida, composição farmacêutica, métodos de tratamentos de distúrbios relacionados à miostatina ou relacionados à ativina a, de doença de desgaste dos músculos, de doença cardiovascular, de distúrbios metabólicos, de células cancerígenas, de doença renal, de doença inflamatória/autoimune, de uma doença de fibrose, de anemia, da dor, da condição de envelhecimento, de distúrbios ósseos, de um desgaste dos músculos ou distúrbio metabólico ou fibrótico ou inflamatório ou relacionado à ativina em indivíduos, e, método de indução do crescimento das células-tronco para o reparo de tecido ou regeneração do órgão em um indivíduo
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
WO2017091706A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
RS62011B1 (sr) 2016-07-15 2021-07-30 Acceleron Pharma Inc Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije
EP3490582B1 (de) 2016-07-27 2024-06-12 Acceleron Pharma Inc. Zusammensetzungen zur verwendung in der behandlung der myelofibrose
MA46472A (fr) 2016-10-05 2019-08-14 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
WO2018067740A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma, Inc. Compositions and method for treating kidney disease
KR20230152811A (ko) 2016-10-05 2023-11-03 악셀레론 파마 인코포레이티드 변이체 actriib 단백질 및 이의 용도
WO2020132647A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
JPWO2020262184A1 (de) * 2019-06-26 2020-12-30

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254678A (en) * 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
EP1333035A3 (de) * 1993-03-19 2004-07-07 The Johns Hopkins University School Of Medicine Wachstumsdifferenzierungsfaktor-8
US5616466A (en) * 1993-11-05 1997-04-01 Cantor; Glenn H. Ribozyme-mediated inhibition of bovine leukemia virus
US6008434A (en) * 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
JPH10502811A (ja) * 1994-07-08 1998-03-17 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−１１
US5674748A (en) * 1995-03-14 1997-10-07 Thomas Jefferson University Human cyclin-dependent kinase-like proteins and methods of using the same
US6124115A (en) * 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
WO1998024925A1 (en) * 1995-11-08 1998-06-11 Medical University Of South Carolina Tissue specific and target rna-specific ribozymes as antimicrobial therapeutics against microbial pathogens
US5824519A (en) * 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
AU6274298A (en) * 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
NO971997D0 (no) * 1997-04-29 1997-04-29 Kjetil Tasken Bruk av immunmodulerende midler
ES2547858T3 (es) * 1997-07-14 2015-10-09 Université de Liège Doble musculación en mamíferos
WO1999006559A1 (en) * 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
AU765832B2 (en) * 1998-07-28 2003-10-02 Johns Hopkins University School Of Medicine, The Growth differentiation factor-11

Also Published As

Publication number Publication date
JP2003517580A (ja) 2003-05-27
WO2000043781A2 (en) 2000-07-27
AU2004203398A1 (en) 2004-08-19
NZ513642A (en) 2004-02-27
EP1147413A2 (de) 2001-10-24
HK1041521B (zh) 2006-11-17
WO2000043781A3 (en) 2001-02-01
CN100567322C (zh) 2009-12-09
BR0008188A (pt) 2002-02-13
MXPA01007366A (es) 2002-06-04
CN1355881A (zh) 2002-06-26
ATE322681T1 (de) 2006-04-15
EP1147413B1 (de) 2006-04-05
CA2359242C (en) 2009-12-08
AU2514000A (en) 2000-08-07
AU772694B2 (en) 2004-05-06
CA2359242A1 (en) 2000-07-27
HK1041521A1 (en) 2002-07-12
DE60027135T2 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
DE60027135D1 (de) Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
MX336500B (es) Insecticida para uso agricola u horticola y metodo para su uso.
BR0210839A (pt) Sistema de recombinação, método para remover uma sequência de dna do dna cromossÈmico de uma célula ou organismo eucarióticos, organismo, cultura de célula, órgão, tecido, parte ou material de propagação transgênico, e, uso de um organismo ou de uma cultura de célula, órgão, tecido, parte ou material de propagação transgênico
NO20005237L (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
ATE305448T1 (de) Phenylalaninderivate als herbizide
EA200500856A1 (ru) Новые химические соединения
DE60141950D1 (de) Vernetzte, nicht von pilzen kommende lipase enthaltende zusammensetzung und methoden zu deren verwendung
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
DE50004334D1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
MXPA02009313A (es) Acilsulfimidas heterociclicas, un metodo para su produccion, agentes que contienen las mismas y su uso como plaguicidas.
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DK0775158T3 (da) Cyclopeptolider
ATE311407T1 (de) Varianten der allergenen proteine der gruppe 2 von dermatophagoides
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
ATE327980T1 (de) 3-heterocyclyl-substituierte benzoesäurederivate
EA200000247A1 (ru) Производные 4-циано-4-деформилсордарицина
BR0316245A (pt) Atividade antimicrobiana de espécie de oxigênio reativo produtora de anticorpos
BR9808210A (pt) Befeniloxazolinas dissubstituìdas
DE602004026838D1 (de) Eine metacaspasen-klasse
DE60207574D1 (de) Verwendung von oxytocin zur stimulierung des pflanzenwachstums
DE50115198D1 (de) Antihelmintika zur verhinderung von parasitären infektionen bei mensch und tier

Legal Events

Date Code Title Description
8364 No opposition during term of opposition